Identification of a blood-based biomarker panel for classification of Alzheimer's disease.

An ideal diagnostic test for Alzheimer's disease (AD) should be non-invasive and easily applicable. Thus, there is a clear need to search for biomarkers in blood. In the present study, we have used multivariate data analysis [support vector machine (SVM)] to investigate whether a blood-based biomarker panel allows discrimination between AD patients and healthy controls at the individual level. We collected a total of 155 serum samples from individuals with early AD and age-matched healthy controls and measured serum levels of 24 markers involved in several biological pathways by ELISA. The dataset was randomly split into a training set for predictor discovery and classification training and a test set for class prediction of blinded samples (3:1 ratio) to evaluate the chosen predictors and parameters. After selection of a feature group of the three most discriminative parameters (cortisol, von Willebrand factor, oxidized LDL antibodies) in the training set, the application of SVM to the training/independent test dataset resulted in an 81.7%/87.1% correct classification for AD and control subjects. In conclusion, we identified a panel of three blood markers, which allowed SVM-based distinguishing of AD patients from healthy controls on a single-subject classification level with clinically relevant accuracy and validity. Blood-based biomarkers might have utility in AD diagnostics as screening tool before further classification with CSF biomarkers and imaging. Future studies should examine whether blood-based biomarkers may also be useful to differentiate AD patients from other dementias.

[1]  C. Romualdi,et al.  Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid‐induced increase in von Willebrand factor: the lesson learned from Cushing syndrome , 2007, British journal of haematology.

[2]  D. Royall,et al.  Alzheimer disease as a vascular disorder: nosological evidence. , 2002, Stroke.

[3]  Michel Verleysen,et al.  The Curse of Dimensionality in Data Mining and Time Series Prediction , 2005, IWANN.

[4]  Ian H. Witten,et al.  Data mining: practical machine learning tools and techniques, 3rd Edition , 1999 .

[5]  Georg Kemmler,et al.  Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.

[6]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[7]  J. C. Torre,et al.  Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .

[9]  A. Remes,et al.  Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease , 2009, Neurobiology of Disease.

[10]  F. Cohen,et al.  Biochemistry and genetics of von Willebrand factor. , 1998, Annual review of biochemistry.

[11]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[12]  C. Laske,et al.  Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[13]  T. Berzin,et al.  Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.

[14]  P. Grant,et al.  Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  H. Benali,et al.  Support vector machine-based classification of Alzheimer’s disease from whole-brain anatomical MRI , 2009, Neuroradiology.

[16]  赤座 至 Endothelial dysfunction associated with hypercortisolism is reversible in Cushing's syndrome , 2010 .

[17]  C. Laske,et al.  Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Aβ 1–42 ratios in CSF in patients with mild Alzheimer’s disease dementia , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[18]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[19]  F. LaFerla,et al.  Alzheimer's disease. , 2010, The New England journal of medicine.

[20]  A. Fagan,et al.  Plasma Cortisol and Progression of Dementia in DAT Subjects , 2006 .

[21]  Thomas Lengauer,et al.  ROCR: visualizing classifier performance in R , 2005, Bioinform..

[22]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[23]  Salvatore Musumeci,et al.  Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status , 2004, Clinical chemistry and laboratory medicine.

[24]  D. Ryglewicz,et al.  Antibodies against oxidized LDL and apolipoprotein E polymorphism in demented patients , 2009, Journal of the Neurological Sciences.

[25]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[26]  L. Parnetti,et al.  Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimer’s Disease , 1996, Thrombosis and Haemostasis.

[27]  Ian Witten,et al.  Data Mining , 2000 .

[28]  T. Yoshimoto,et al.  Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushing's syndrome. , 2010, Endocrine journal.

[29]  A. Fagan,et al.  Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. , 2006, The American journal of psychiatry.

[30]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[31]  Michel Verleysen,et al.  Nonlinear Dimensionality Reduction , 2021, Computer Vision.

[32]  Pablo Moscato,et al.  Identification of a 5-Protein Biomarker Molecular Signature for Predicting Alzheimer's Disease , 2008, PloS one.

[33]  W. Maetzler,et al.  Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. , 2010, Current Alzheimer research.

[34]  S. Soekadar,et al.  BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. , 2007, Journal of psychiatric research.

[35]  C. Laske,et al.  Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? , 2008, Journal of Alzheimer's disease : JAD.

[36]  H. Vankova Mini Mental State , 2010 .

[37]  Takashi Takenouchi,et al.  Statistical Learning Theory by Boosting Method , 2004 .

[38]  C. Laske,et al.  Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[39]  J. Ryu,et al.  A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.